Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Childhood Absence Epilepsy Treatment Market to Witness Strong Growth of Typical Absence Seizure Segment - QYR Consulting

This image opens in the lightbox

News provided by

QY Research

24 Jun, 2019, 13:30 GMT

Share this article

Share toX

Share this article

Share toX

LOS ANGELES, June 24, 2019 /PRNewswire/ -- Absence seizures in children are recurrent and brief episodes of the unconscious state generally accompanies by autonomic components or atonic and, simple automatism or clonic. Typical and atypical are two types of absence seizure. Typical absence seizure commonly arises in children with normal intelligence or development and last for nearly 10 seconds. On the other hand, atypical absences seizures mainly arise in children with neurologic disabilities such as Lennox-Gastaut syndrome and with severe learning.

According to Science Daily, recently a team at RIKEN Center for Brain Science in Japan proved that the primary reason that triggers absence epilepsy is weakened communication between striatum and cortex- the two regions of the brain.

Some of the well-known treatments available in the market at the moment are valproic acid, ethosuximide, and lamotrigine. Out of these treatments, ethosuximide is the most popular and helpful one as it assists the patient in controlling typical absence seizures.

Key Takeaways of the Global Childhood Absence Epilepsy Treatment Market

  • North America and Europe are potentially promising markets throughout the forecasted period
  • Various initiatives are being taken by pharmaceutical companies as well as healthcare providers to meet the needs of patients with absence epilepsy
  • Side effects associated with the medication hampers the growth of the market
  • Typical absence seizure segment is expected to lead the market in the years to come
  • Few capsules used to treat absence epilepsy such as Zarontin and Emeside are discontinued from production

Report TOC, Figures and Table@ https://www.qyrconsulting.com/reports/global-childhood-absence-epilepsy-treatment-market

Inclusion of Pricing Strategy of the Key Players Make this Report an Exclusive One

A Comprehensive assessment of the global childhood absence epilepsy treatment market is provided in this lucid report. The estimation has been done on the basis of various key segments, market size, key dynamics, and competitive analysis. The comparison between revenue and volume, revenue share comparison and Year-on-Year growth comparison of various segments of this market have mentioned in the report prepared by QY Research.

Some other characteristics of the global childhood absence epilepsy treatment market are pricing strategy of the top players functioning in the market. The projection factors and overall scenario have also been discussed in detail in an attempt to understand the trends and opportunities of this market.

Regional trends affecting the growth of the market have been thoroughly discussed. The report also sheds light on the activity of various segments in the covered regions.

Market Taxonomy

  • Typical Absence Seizures
  • Atypical Absence Seizures

Typical absence seizure is likely to lead the market as it is more commonly found in children with epilepsy. The treatment associated with this type of childhood epilepsy is different as, the typical absence is basically different and is unique in terms of pharmacology compared to atypical absence epilepsy.

The report has examined the growth dynamics of childhood absence epilepsy market in key regions. The study keeps a track of protuberant trends strengthening the demand for novel drugs in the regions and also take a glance at unmet necessities of the developing markets. Developed economies, especially North America region is expected to lead the market. The existence of specialty pharmaceutical manufacturers in the North America region is the primary factor which has created lucrative opportunities in the region.

Review Sample Report@ https://www.qyrconsulting.com/request-sample/7275

Competitive Landscape

Teva Pharmaceutical Industries Ltd., Cavion, Inc., AbbVie, Inc., Pfizer, Inc., Insys Therapeutics, Inc., and GlaxoSmithKline Plc. are some of the key players operating in the global childhood absence epilepsy treatment market.

Key Market Dynamics

 Higher prevalence of absence epilepsy amongst the children in developing regions and rising incidence in low-income countries is the primary factor which is fuelling the growth of the market. The huge economic burden of epilepsy in kids across the globe is also boosting the growth of the global childhood absence epilepsy treatment during the projected period.

The growing incidence of typical absence seizures in youngsters, particularly in rural areas is one of the significant factors which is creating robust growth of the global childhood absence epilepsy treatment market.

For Custom Childhood Absence Epilepsy Treatment Report @ https://www.qyrconsulting.com/customize-request/7275

Related Reports:

Biopharmaceutical Third Party Logistics Market: https://www.qyrconsulting.com/reports/global-biopharmaceutical-third-party-logistics

Nutrigenomics Market: https://www.qyrconsulting.com/reports/global-nutrigenomics-market

Rabies Diagnostics Market: https://www.qyrconsulting.com/reports/global-rabies-diagnostics-market

Media Contact:

Rahul Singh
Digital Marketing Director
Contact: +91-7028920828
Email: rahul@qyrconsulting.com

Sales Contact US:

USA Registered Office:

QY Research, INC.
17890 Castleton, Suite 218,
City of industry, CA - 91748 
USA: +1-626-428-8800
Emails – sales@qyrconsulting.com
Web
– https://www.qyrconsulting.com/

Logo: https://mma.prnewswire.com/media/719476/QY_Research_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.